Physician profile
Won I Kim
NPI 1366536153
$8,336.17
in general payments reported to CMS, 2019-2025
21 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2022: $854 · 2023: $2,578 · 2024: $3,783 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,373 · Travel and Lodging: $970 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,373.09 |
| Travel and Lodging | $970.33 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,436.41 | 2022-2025 | |
| Alcon Vision LLC | $2,030.97 | 2022-2025 | Clareon, Rocklatan, Argos |
| New World Medical,INC. | $587.28 | 2022-2024 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Sight Sciences, INC. | $542.06 | 2021-2025 | Omni Surgical System, Tearcare System, Sion Surgical Instrument |
| Sun Pharmaceutical Industries INC. | $457.80 | 2023-2025 | Cequa |
| Glaukos Corporation | $342.84 | 2022-2025 | Idosetr, Istent Infinite, Istent |
| Oyster Point Pharma, INC. | $275.87 | 2023-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $218.11 | 2022-2025 | Miebo, Vyzulta |
| Apellis Pharmaceuticals, INC. | $216.75 | 2022-2023 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $209.49 | 2024-2025 | Xdemvy |
| Rxsight INC | $189.91 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Biotissue Holdings INC. | $171.44 | 2022-2023 | |
| Genentech USA, INC. | $126.88 | 2025 | Susvimo |
| Astellas Pharma US INC | $110.93 | 2024 | Izervay |
| Ivantis, INC | $106.06 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $93.97 | 2023 | Artevo 800 |
| Johnson & Johnson Surgical Vision, INC. | $63.99 | 2023 | Tecnis Iol, Tecnis Simplicity, Veritas Vision System |
| Harrow Eye, LLC | $54.32 | 2024-2025 | Vevye |
| Allergan, INC. | $49.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $31.85 | 2022 | |
| Thea Pharma INC. | $19.80 | 2023 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Won Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.